Structure Therapeutics Inc. 4

Chief Commercial Officer John Joseph Berrios received stock options on 140,766 Ordinary Shares at $17.54 and an award of 174,612 RSUs of Structure Therapeutics Inc. on 2026-08-06.

On August 6, 2026, John Joseph Berrios, Chief Commercial Officer of Structure Therapeutics Inc., received two equity compensation awards: a stock option grant for 140,766 Ordinary Shares at an exercise price of $17.54 per share, and a grant of 174,612 restricted share units (RSUs), each representing one Ordinary Share. The option award vests over four years, with one-fourth vesting on the first anniversary of August 6, 2026 and the remainder vesting in 36 equal monthly installments thereafter, contingent on continued service, while the RSUs vest in four equal annual installments on each anniversary of August 6, 2026, also subject to continued service. Following these awards, Berrios beneficially owns 174,612 Ordinary Shares (underlying the RSUs) directly, in addition to the newly granted option position, aligning his compensation further with shareholder interests. Because the filing does not provide a trading price for Ordinary Shares beyond the $17.54 option strike, the value of both the awards and his post-transaction holdings is approximated using that price, implying an estimated grant value of roughly $2.47 million for the RSUs and $2.47 million in option notional value, and an ownership value of about $3.06 million for the directly held Ordinary Shares.

Filing Facts

CIK

1888886

Ticker

GPCR

Form

4

Source Type

fda

Accession

0002148420-26-000006

Alert Tier

7